February 7, 2011

HELIX BIOPHARMA CORP. RECEIVES FDA IND APPROVAL TO CONDUCT A U.S. PHASE I CLINICAL STUDY WITH ITS LUNG CANCER DRUG CANDIDATE L-DOS47 (PDF)

AURORA, Ontario, February 7, 2011 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a developer of
biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has received approval for its investigational new drug (“IND”) application from the United States Food and Drug Administration (“FDA”) to perform its planned U.S. Phase I clinical safety and tolerability study of its lung cancer drug candidate L-DOS47.